Yixintang Pharmaceutical Group002727.SZValuation Analysis

As of Oct 19, 2026, Yixintang Pharmaceutical Group (002727.SZ) trades at a P/E of 28.10x, P/B of 1.03x, P/S of 0.45x, and a dividend yield of 3.02%.
Longitudinal percentile comparison: P/E sits at the 64th percentile over the trailing 10Y window (vs. 54th percentile over 3Y); P/B sits at the 13th percentile over the trailing 10Y window (vs. 40th percentile over 3Y); P/S sits at the 16th percentile over the trailing 10Y window (vs. 52nd percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 37th percentile within its industry and the 39th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 4.99%, ranking at the 94th percentile over the trailing 20Y window.
Notably, P/E and P/B aren't telling quite the same story, 51.6 points apart — worth checking the full percentile matrix on this page for the complete picture. Its P/E percentile is roughly the same whether measured against the industry or the broader market. Of the 4.99% total shareholder yield, 3.02% is paid out as dividends and roughly 1.97% is implied to come from buybacks — both channels are meaningfully in play. Yixintang Pharmaceutical Group operates in the Medicine sector. Data refreshes weekly and is for reference only, not investment advice.